24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore
11 affiliations
- 1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 2Department of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, South Korea
- 3Department of Orthopedics and Orthopedic Research Center, Kaohsiung Medical University Hospital, College of Medicine, Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
- 4Amgen Inc., Thousand Oaks, CA USA
- 5Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong, China
- 6Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China
- 7Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
- 8Amgen Australia, Sydney, Australia
- 9Department of Medicine, Amgen Europe, Amgen GmbH, Suurstoffi 22, 6343 Rotkreuz, Switzerland
- 10Real World Solutions, IQVIA Solutions Asia, Singapore, Singapore
- 11Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Abstract
Introduction: To compare 24-month persistence and compliance of denosumab with alendronate in postmenopausal women with osteoporosis across 5 Asia–Pacific territories.
Materials and methods: This prospective cohort study included women aged ≥ 50 years from Australia, Taiwan, South Korea, Hong Kong, and Singapore. Participants received either a bi-annual denosumab injection or weekly oral alendronate as osteoporosis treatment, based on physician judgment. Multivariable logistic regression assessed whether therapy (denosumab or alendronate) was significantly associated with treatment persistence and compliance over 24 months of follow-up. The models were adjusted for age, fracture history, baseline bone mineral density (BMD), prior osteoporosis therapy, and prior oral glucocorticoid treatment. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated.
Results: Among 687 enrolled patients, 549 completed their 24-month visit (295 in denosumab and 254 in alendronate group). Patients in the denosumab group were older and a higher proportion previously received osteoporosis treatment. Overall treatment persistence and compliance were 74.9% and 56.6%, respectively. Patients prescribed with denosumab exhibited higher persistence (86.1% vs. 61.8%; P < 0.001) and compliance (62.4% vs. 50.0%; P = 0.004), compared with those on alendronate. Regression results also demonstrated that patients receiving denosumab were more likely to be persistent (aOR = 3.91; 95% CI 2.52–6.08), and compliant (aOR = 1.61; 95% CI 1.12–2.31). BMD T-scores improved in both the treatment groups after 24 months with no significant association between treatment type and change in T-score. No significant difference was also observed in the occurrence of adverse events between the two treatment cohorts. Patients on alendronate reported gastrointestinal issues more frequently, whereas those on denosumab had a higher incidence of bone and joint injuries.
Conclusion: Postmenopausal women with osteoporosis were more likely to be persistent and compliant with a bi-annual denosumab injection, compared with weekly oral alendronate.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00774-026-01736-w.
Related
- Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China.
- Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3-Year Prospective Study.
- Prevalence and risk factors of postmenopausal osteoporosis: a systematic review and meta-analysis based on multivariate logistic regression
- Association of elevated circulating iron with bone mineral density and bone turnover markers in postmenopausal Saudi women with and without osteoporosis
- Effect of Transcutaneous Electrical Acupoint Stimulation on Postmenopausal Osteoporosis-Related Pain: Study Protocol for a Randomized, Sham-Controlled Trial
BibTeX
@article{lau202624month,
title = {{24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore}},
author = {Tang Ching Lau and Dong-Gune Chang and Chung-Hwan Chen and Shuang Huang and Edith M. C. Lau and Sheung-Wai Law and Young-Kyun Lee and Cae Tolman and Laura Canals and See-Hwee Yeo and Peter R. Ebeling},
journal = {Journal of Bone and Mineral Metabolism},
year = {2026},
month = jun,
doi = {10.1007/s00774-026-01736-w},
url = {https://doi.org/10.1007/s00774-026-01736-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - 24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore
AU - Tang Ching Lau
AU - Dong-Gune Chang
AU - Chung-Hwan Chen
AU - Shuang Huang
AU - Edith M. C. Lau
AU - Sheung-Wai Law
AU - Young-Kyun Lee
AU - Cae Tolman
AU - Laura Canals
AU - See-Hwee Yeo
AU - Peter R. Ebeling
PY - 2026
DA - 2026/06/17
JO - Journal of Bone and Mineral Metabolism
DO - 10.1007/s00774-026-01736-w
UR - https://doi.org/10.1007/s00774-026-01736-w
AB - Introduction: To compare 24-month persistence and compliance of denosumab with alendronate in postmenopausal women with osteoporosis across 5 Asia–Pacific territories. Materials and methods: This prospective cohort study included women aged ≥ 50 years from Australia, Taiwan, South Korea, Hong Kong, and Singapore. Participants received either a bi-annual denosumab injection or weekly oral alendronate as osteoporosis treatment, based on physician judgment. Multivariable logistic regression assessed whether therapy (denosumab or alendronate) was significantly associated with treatment persistence and compliance over 24 months of follow-up. The models were adjusted for age, fracture history, baseline bone mineral density (BMD), prior osteoporosis therapy, and prior oral glucocorticoid treatment. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated. Results: Among 687 enrolled patients, 549 completed their 24-month visit (295 in denosumab and 254 in alendronate group). Patients in the denosumab group were older and a higher proportion previously received osteoporosis treatment. Overall treatment persistence and compliance were 74.9% and 56.6%, respectively. Patients prescribed with denosumab exhibited higher persistence (86.1% vs. 61.8%; P < 0.001) and compliance (62.4% vs. 50.0%; P = 0.004), compared with those on alendronate. Regression results also demonstrated that patients receiving denosumab were more likely to be persistent (aOR = 3.91; 95% CI 2.52–6.08), and compliant (aOR = 1.61; 95% CI 1.12–2.31). BMD T-scores improved in both the treatment groups after 24 months with no significant association between treatment type and change in T-score. No significant difference was also observed in the occurrence of adverse events between the two treatment cohorts. Patients on alendronate reported gastrointestinal issues more frequently, whereas those on denosumab had a higher incidence of bone and joint injuries. Conclusion: Postmenopausal women with osteoporosis were more likely to be persistent and compliant with a bi-annual denosumab injection, compared with weekly oral alendronate. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00774-026-01736-w.
SN - 0914-8779
SN - 1435-5604
ER -